18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          The high demand for genetic tests and limited supply of genetics professionals has created a need for alternative service delivery models. Digital tools are increasingly being used to support multiple points in the genetic testing journey; however, none are transferable across multiple clinical specialties and settings nor do they encompass the entire trajectory of the journey. We aim to evaluate the effectiveness of the Genetics Adviser, an interactive, patient-facing, online digital health tool that delivers pre-test counselling, provides support during the waiting period for results, and returns results with post-test counselling, encompassing the entire patient genetic testing journey.

          Methods and analysis

          We will compare the Genetics Adviser paired with a brief genetic counselling session to genetic counselling alone in a randomised controlled trial. One hundred and forty patients who previously received uninformative genetic test results for their personal and family history of cancer will be recruited from familial cancer clinics in Toronto and offered all clinically significant results from genomic sequencing. Participants randomised into the intervention arm will use the Genetics Adviser to learn about genomic sequencing, receive pre-test counselling, support during the waiting period and results, supplemented with brief counselling from a genetic counsellor. Participants in the control arm will receive standard pre-test and post-test counselling for genomic sequencing from a genetic counsellor. Our primary outcome is decisional conflict following pre-test counselling from the Genetics Adviser+genetic counsellor or counsellor alone. Secondary outcomes include: knowledge, satisfaction with decision-making, anxiety, quality of life, psychological impact of results, empowerment, acceptability and economic impact for patients and the health system. A subset of patients will be interviewed to assess user experience.

          Ethics and dissemination

          This study has been approved by Clinical Trials Ontario Streamlined Research Ethics Review System (REB#20–035). Results will be shared through stakeholder workshops, national and international conferences and peer-reviewed journals.

          Trial registration number

          NCT04725565.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: not found
          • Article: not found

          Using thematic analysis in psychology

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            SPIRIT 2013 statement: defining standard protocol items for clinical trials.

            The protocol of a clinical trial serves as the foundation for study planning, conduct, reporting, and appraisal. However, trial protocols and existing protocol guidelines vary greatly in content and quality. This article describes the systematic development and scope of SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013, a guideline for the minimum content of a clinical trial protocol.The 33-item SPIRIT checklist applies to protocols for all clinical trials and focuses on content rather than format. The checklist recommends a full description of what is planned; it does not prescribe how to design or conduct a trial. By providing guidance for key content, the SPIRIT recommendations aim to facilitate the drafting of high-quality protocols. Adherence to SPIRIT would also enhance the transparency and completeness of trial protocols for the benefit of investigators, trial participants, patients, sponsors, funders, research ethics committees or institutional review boards, peer reviewers, journals, trial registries, policymakers, regulators, and other key stakeholders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials

              High quality protocols facilitate proper conduct, reporting, and external review of clinical trials. However, the completeness of trial protocols is often inadequate. To help improve the content and quality of protocols, an international group of stakeholders developed the SPIRIT 2013 Statement (Standard Protocol Items: Recommendations for Interventional Trials). The SPIRIT Statement provides guidance in the form of a checklist of recommended items to include in a clinical trial protocol. This SPIRIT 2013 Explanation and Elaboration paper provides important information to promote full understanding of the checklist recommendations. For each checklist item, we provide a rationale and detailed description; a model example from an actual protocol; and relevant references supporting its importance. We strongly recommend that this explanatory paper be used in conjunction with the SPIRIT Statement. A website of resources is also available (www.spirit-statement.org). The SPIRIT 2013 Explanation and Elaboration paper, together with the Statement, should help with the drafting of trial protocols. Complete documentation of key trial elements can facilitate transparency and protocol review for the benefit of all stakeholders.
                Bookmark

                Author and article information

                Journal
                BMJ Open
                BMJ Open
                bmjopen
                bmjopen
                BMJ Open
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2044-6055
                2022
                29 April 2022
                : 12
                : 4
                : e060899
                Affiliations
                [1 ]departmentInstitute of Health Policy, Management and Evaluation , University of Toronto , Toronto, Ontario, Canada
                [2 ]departmentLi Ka Shing Knowledge Institute , St Michael's Hospital, Unity Health Toronto , Toronto, Ontario, Canada
                [3 ]departmentMarvelle Koffler Breast Centre, Mount Sinai Hospital , Sinai Health System , Toronto, Ontario, Canada
                [4 ]departmentDepartment of Molecular Genetics , University of Toronto , Toronto, Ontario, Canada
                [5 ]departmentZane Cohen Centre, Mount Sinai Hospital , Sinai Health System , Toronto, Ontario, Canada
                [6 ]The Hospital for Sick Children , Toronto, Ontario, Canada
                [7 ]Sunnybrook Health Sciences Centre , Toronto, Ontario, Canada
                [8 ]Princess Margaret Cancer Centre , Toronto, Ontario, Canada
                [9 ]GeneDx Inc , Gaithersburg, Maryland, USA
                [10 ]University Health Network , Toronto, Ontario, Canada
                [11 ]departmentFaculty of Medicine , University of Toronto , Toronto, Ontario, Canada
                [12 ]departmentRay D Wolfe Department of Family Medicine, Mount Sinai Hospital , Sinai Health System , Toronto, Ontario, Canada
                [13 ]departmentDepartment of Family and Community Medicine , University of Toronto , Toronto, Ontario, Canada
                [14 ]departmentCentre for Global eHealth Innovation, Techna Institute , University Health Network , Toronto, Ontario, Canada
                [15 ]departmentMelbourne School of Population and Global Health , The University of Melbourne , Melbourne, Victoria, Australia
                [16 ]departmentDepartment of Surgery , University of Toronto , Toronto, Ontario, Canada
                [17 ]Workplace Safety and Insurance Board , Toronto, Ontario, Canada
                [18 ]Ontario Disability Coalition , Toronto, Ontario, Canada
                [19 ]departmentApplied Health Research Centre (AHRC) , Li Ka Shing Knowledge Institute of St Michael's Hospital , Toronto, Ontario, Canada
                [20 ]departmentDalla Lana School of Public Health , University of Toronto , Toronto, Ontario, Canada
                [21 ]BC Cancer , Vancouver, British Columbia, Canada
                [22 ]departmentDepartment of Medical Genetics , The University of British Columbia , Vancouver, British Columbia, Canada
                [23 ]departmentPathology and Laboratory Medicine , Mount Sinai Hospital, Sinai Health System , Toronto, Ontario, Canada
                [24 ]departmentDepartment of Laboratory Medicine and Pathobiology , University of Toronto , Toronto, Ontario, Canada
                [25 ]departmentLunenfeld Tanenbaum Research Institute , Sinai Health System , Toronto, Ontario, Canada
                [26 ]departmentFred A Litwin and Family Centre in Genetic Medicine , University Health Network , Toronto, Ontario, Canada
                Author notes
                [Correspondence to ] Dr Yvonne Bombard; yvonne.bombard@ 123456utoronto.ca
                Author information
                http://orcid.org/0000-0003-3685-5679
                http://orcid.org/0000-0002-2147-8674
                http://orcid.org/0000-0002-9516-4539
                Article
                bmjopen-2022-060899
                10.1136/bmjopen-2022-060899
                9058789
                35487723
                73762c5e-f0de-4f56-b621-2e07ef71eb38
                © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 07 January 2022
                : 24 March 2022
                Funding
                Funded by: University of Toronto McLaughlin Centre;
                Award ID: MC-2018-04
                Funded by: FundRef http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Award ID: 165963,143310
                Funded by: FundRef http://dx.doi.org/10.13039/100015150, St. Michael's Hospital Foundation;
                Award ID: N/A
                Categories
                Genetics and Genomics
                1506
                1697
                Protocol
                Custom metadata
                unlocked

                Medicine
                genetics,health policy,clinical trials
                Medicine
                genetics, health policy, clinical trials

                Comments

                Comment on this article